Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic antibodies. Its lead product candidate is Eptinezumab, a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). Its being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. The company is also evaluating ALD1910, which is designed to specifically inhibit pituitary adenylate cyclase-activating peptide-38. Alder was founded in 2002 and is headquartered in Bothell, Washington.